Clinical Research
Construction and validation of a risk prediction model for myelosuppression in elderly lung cancer patients undergoing chemotherapy
Chen Li, Zou Shengqiang, Jiang Zhuyue, Hu Jiamin, Yan Xiaoxin, Yao Yaji, Liu Jinhan
Published 2021-05-16
Cite as Chin J Mod Nurs, 2021, 27(14): 1848-1853. DOI: 10.3760/cma.j.cn115682-20200831-05137
Abstract
ObjectiveTo explore the risk factors for myelosuppression in elderly lung cancer patients undergoing chemotherapy and construct a risk prediction model for myelosuppression in elderly lung cancer patients undergoing chemotherapy.
MethodsUsing the convenient sampling method, data of 228 elderly patients with lung cancer undergoing chemotherapy in Respiratory Department of a Class Ⅲ Grade A hospital in Zhenjiang from May 2018 to May 2019 were selected, and risk factors of adverse reactions of myelosuppression in patients were analyzed statistically. The binomial Logistic regression was applied to construct the prediction model and the area under the ROC curve was used to test the prediction effect of the model. The patient data from January to May 2020 were collected to validate the model.
ResultsAmong the 228 patients, 75 patients developed myelosuppression, with an incidence of 32.89%. Multivariate analysis results showed that platinum-containing chemotherapy regimens, combined with other adverse reactions, decreased albumin before chemotherapy and decreased hemoglobin before chemotherapy were independent risk factors for myelosuppression in elderly lung cancer patients during chemotherapy (P<0.05) , which were included in the model. The area under the ROC curve of the final model was 0.823, the maximum Youden index was 0.5, sensitivity was 81.3%, and specificity was 70.5%. The results of the verification data showed that the area under the ROC curve was 0.846, sensitivity was 90.4% and specificity was 68.2%.
ConclusionsThe prediction effect of this model is good, which can provide reference basis for clinical treatment and formulating nursing measures to prevent myelosuppression.
Key words:
Aged; Lung neoplasms; Chemotherapy; Myelosuppression; Risk prediction model
Contributor Information
Chen Li
Department of Oncology, the Third People's Hospital of Zhenjiang, Jiangsu University, Zhenjiang 212005, China
Zou Shengqiang
Department of Oncology, the Third People's Hospital of Zhenjiang, Jiangsu University, Zhenjiang 212005, China
Department of Critical Care Medicine, the Third People's Hospital of Zhenjiang, Jiangsu University, Zhenjiang 212005, China
Jiang Zhuyue
Department of Oncology, the Third People's Hospital of Zhenjiang, Jiangsu University, Zhenjiang 212005, China
Hu Jiamin
Department of Oncology, the Third People's Hospital of Zhenjiang, Jiangsu University, Zhenjiang 212005, China
Yan Xiaoxin
Department of Oncology, the Third People's Hospital of Zhenjiang, Jiangsu University, Zhenjiang 212005, China
Yao Yaji
Department of Oncology, the Third People's Hospital of Zhenjiang, Jiangsu University, Zhenjiang 212005, China
Liu Jinhan
Department of Oncology, the Third People's Hospital of Zhenjiang, Jiangsu University, Zhenjiang 212005, China